CKD transferred KRW 24B to its two R&D subsidiares in a year

Chong Kun Dang established Neurateon six months after establishing Archela last year…split roles of clinical development and product development

Invested KRW 10.7 billion to Archela·KRW 10.5 billion to Neurateon…both subsidiaries have yet to generate outcomes

Chong Kun Dang is accelerating its research and development (R&D) strength by establishing separate corporate entities for its research organizations. Over the past year alone, the company's capital contributions to two newly spun-off entities have exceeded KRW 24 billion. Attention is focused on whether this specialized R&D subsidiary framework will translate into performance.

According to the Financial Supervisory Service, on the 1st, Chong Kun Dang invested an additional KRW 10.7 billion into Archela, its specialized drug development subsidiary, in the second quarter. Following an initial KRW 3.0 billion investment when Archela was established last year, this additional capital transfer within roughly six months raised Chong Kun Dang's cumulative investment in Archela to KRW 13.7 billion.

Archela was founded in October of last year as a drug development subsidiary designed to enhance specialized expertise and operational efficiency in novel drug development. It operates as a wholly owned subsidiary of Chong Kun Dang, with Chong Kun Dang's equity stake in Archela standing at KRW 8.2 billion as of the end of June.

Rather than discovering preclinical candidates in-house, Archela adopts a No Research, Development Only (NRDO) business model focused on advancing transferred clinical-stage pipeline candidates toward regulatory approval and commercialization. The subsidiary has obtained three pipeline candidates previously developed by Chong Kun Dang: the dyslipidemia candidate 'CKD-508,' the obesity and diabetes candidate 'CKD-514,' and the intractable neurological disease candidate 'CKD-513,' and is currently driving their clinical progression and commercial development.

Dr. Ju-Hee Lee, formerly of the Chong Kun Dang Research Institute, was appointed as Archela's first chief executive officer. Dr. Lee is a drug development expert who obtained a doctoral degree from Seoul National University and accumulated extensive research experience at the Seoul National University College of Medicine Samsung Cancer Research Institute and Memorial Sloan Kettering Cancer Center (MSKCC) in the United States.

Archela's board of directors currently comprises three members: Dr. Lee, alongside non-executive directors Sang-yoon Lee and Chang-sik Lee. Director Sang-yoon Lee is an internist who graduated from Seoul National University College of Medicine and built global clinical development experience at Pfizer and Bridge Biotherapeutics. Director Chang-sik Lee, head of the Chong Kun Dang New Drug Research Institute, has spearheaded small-molecule synthetic drug research, pipeline discovery, and early development. While Sung-jun Min, head of Chong Kun Dang's Clinical Development Center, initially served on the founding board, he later stepped down, and Sang-yoon Lee joined the board.

Following its additional capital contribution to Archela, Chong Kun Dang also committed capital to a newly established subsidiary. In April of this year, six months after launching Archela, Chong Kun Dang established Neurateon and invested 10.5 billion KRW during the first half of the year. Chong Kun Dang initially acquired equity by investing KRW 500 million at Neurateon's incorporation, then expanded its total investment to KRW 10.5 billion through a capital increase.

Chong Kun Dang established the R&D subsidiary Neurateon to specialize in technical research functions such as pharmaceutical formulation, analytical research, and product development. Neurateon is likewise a wholly owned subsidiary, with Chong Kun Dang holding a 100% equity stake.

Archela focuses on clinical development and out-licensing of novel pipeline assets transferred from Chong Kun Dang, whereas Neurateon specializes in formulation and analytical research, as well as product development capabilities for incrementally modified drugs (IMDs) and generics. Chong Kun Dang has thus split the roles of its R&D subsidiaries into Archela, which focuses on late-stage candidate development, and Neurateon, which oversees the technical research needed for commercial formulation and manufacturing.

Neurateon's executive composition is similarly tailored to the commercialization stages of formulation, product development, and manufacturing. Inaugural CEO Dong-han Won is a formulation research specialist who conducted formulation and technical research at Dong-A ST for over two decades before serving as head of the Technology Research Institute at Chong Kun Dang. On the board of directors, Yu-Kyung Kwon, head of the Development Center at Chong Kun Dang, and Hyungwon Byun, head of the Manufacturing Division, serve as non-executive directors to support product development and regulatory affairs, as well as manufacturing and quality management, respectively.

With these investments, Chong Kun Dang has invested a total of KRW 24.2 billion into the two newly established R&D subsidiaries over the past year. With Chong Kun Dang's consolidated operating profit last year at KRW 80.6 billion, the company effectively allocated about 30% of its annual operating earnings to the two specialized R&D subsidiaries in less than a year.

However, neither subsidiary has yet reached the stage of generating substantial financial performance. In the first half of this year, Archela recorded a net loss of 5.3 billion KRW with zero revenue. During the same period, Neurateon recorded no revenue and no net profit or loss.